Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial

In the primary analysis of the DRIVE-SHIFT trial, switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression of HIV-1 through week 48. Here, we present long-term efficacy and safety outcomes through week 144 of the DRIVE-SHIFT trial. METHODS: This phase 3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Wan, Hong, Xu, Zhi Jin, Morais, Cristiana, Sklar, Peter, Greaves, Wayne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126485/
https://www.ncbi.nlm.nih.gov/pubmed/33633036
http://dx.doi.org/10.1097/QAI.0000000000002642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126485/
https://www.ncbi.nlm.nih.gov/pubmed/33633036
http://dx.doi.org/10.1097/QAI.0000000000002642

Ejemplares similares